News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
288,258 Results
Type
Article (18999)
Company Profile (162)
Press Release (269092)
Multimedia
Podcasts (87)
Webinars (3)
Section
Business (71135)
Career Advice (104)
Deals (12228)
Drug Delivery (64)
Drug Development (54704)
Employer Resources (30)
FDA (8930)
Job Trends (6036)
News (142953)
Policy (11874)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (3)
Academia (1058)
Academic (1)
Accelerated approval (31)
Adcomms (24)
Allergies (71)
Alliances (19671)
ALS (136)
Alzheimer's disease (1145)
Antibody-drug conjugate (ADC) (283)
Approvals (9134)
Artificial intelligence (266)
Autoimmune disease (134)
Automation (17)
Bankruptcy (86)
Best Places to Work (5607)
BIOSECURE Act (13)
Biosimilars (105)
Biotechnology (114)
Bladder cancer (139)
Brain cancer (57)
Breast cancer (545)
Cancer (4092)
Cardiovascular disease (319)
Career advice (101)
Career pathing (4)
CAR-T (305)
CDC (8)
Celiac Disease (1)
Cell therapy (819)
Cervical cancer (18)
Clinical research (48416)
Collaboration (1258)
Company closure (2)
Compensation (598)
Complete response letters (51)
COVID-19 (1118)
CRISPR (88)
C-suite (531)
Cystic fibrosis (132)
Data (5004)
Denatured (11)
Depression (109)
Diabetes (347)
Diagnostics (1919)
Digital health (22)
Diversity (2)
Diversity, equity & inclusion (6)
Drug discovery (172)
Drug pricing (89)
Drug shortages (20)
Duchenne muscular dystrophy (213)
Earnings (29904)
Editorial (22)
Employer branding (5)
Employer resources (28)
Events (49379)
Executive appointments (565)
FDA (11148)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (10)
Frontotemporal dementia (19)
Funding (950)
Gene editing (187)
Generative AI (23)
Gene therapy (669)
GLP-1 (653)
Government (1623)
Grass and pollen (1)
Guidances (213)
Healthcare (8464)
HIV (39)
Huntington's disease (42)
IgA nephropathy (75)
Immunology and inflammation (201)
Immuno-oncology (47)
Indications (80)
Infectious disease (1219)
Inflammatory bowel disease (146)
Inflation Reduction Act (5)
Influenza (31)
Intellectual property (157)
Interviews (13)
IPO (6770)
IRA (20)
Job creations (745)
Job search strategy (88)
JPM (44)
Kidney cancer (10)
Labor market (22)
Layoffs (260)
Leadership (4)
Legal (1353)
Liver cancer (65)
Longevity (11)
Lung cancer (572)
Lymphoma (361)
Machine learning (22)
Management (7)
Manufacturing (506)
MASH (130)
Medical device (4493)
Medtech (4512)
Mergers & acquisitions (6114)
Metabolic disorders (926)
Multiple sclerosis (130)
NASH (14)
Neurodegenerative disease (264)
Neuropsychiatric disorders (77)
Neuroscience (2131)
Neurotech (1)
NextGen: Class of 2026 (2335)
Non-profit (1356)
Now hiring (11)
Obesity (441)
Opinion (129)
Ovarian cancer (140)
Pain (149)
Pancreatic cancer (176)
Parkinson's disease (242)
Partnered (16)
Patents (301)
Patient recruitment (386)
Peanut (35)
People (21740)
Pharmaceutical (34)
Pharmacy benefit managers (10)
Phase 1 (15061)
Phase 2 (21720)
Phase 3 (16431)
Pipeline (3720)
Policy (134)
Postmarket research (1593)
Preclinical (5676)
Press Release (47)
Prostate cancer (205)
Psychedelics (51)
Radiopharmaceuticals (217)
Rare diseases (761)
Real estate (1530)
Recruiting (14)
Regulatory (11991)
Reports (19)
Research institute (1283)
Resumes & cover letters (10)
Rett syndrome (26)
RNA editing (14)
RSV (27)
Schizophrenia (116)
Series A (168)
Series B (134)
Service/supplier (4)
Sickle cell disease (86)
Special edition (15)
Spinal muscular atrophy (137)
Sponsored (25)
Startups (1538)
Stomach cancer (15)
Supply chain (51)
Tariffs (35)
The Weekly (75)
Vaccines (358)
Venture capital (63)
Weight loss (270)
Women's health (34)
Worklife (1)
Date
Today (2)
Last 7 days (396)
Last 30 days (1385)
Last 365 days (19764)
2026 (1882)
2025 (19883)
2024 (21649)
2023 (23305)
2022 (28008)
2021 (29214)
2020 (24925)
2019 (18392)
2018 (13583)
2017 (14565)
2016 (12651)
2015 (14606)
2014 (9683)
2013 (7058)
2012 (7170)
2011 (7229)
2010 (6458)
Location
Africa (168)
Alabama (49)
Alaska (3)
Arizona (91)
Arkansas (5)
Asia (17828)
Australia (3027)
California (7139)
Canada (1585)
China (909)
Colorado (226)
Connecticut (331)
Delaware (232)
Europe (41805)
Florida (987)
Georgia (199)
Hawaii (2)
Idaho (21)
Illinois (441)
India (53)
Indiana (263)
Iowa (13)
Japan (317)
Kansas (58)
Kentucky (25)
Louisiana (12)
Maine (7)
Maryland (810)
Massachusetts (5718)
Michigan (89)
Minnesota (324)
Mississippi (2)
Missouri (94)
Montana (9)
Nebraska (3)
Nevada (68)
New Hampshire (33)
New Jersey (2059)
New Mexico (16)
New York (1890)
North Carolina (986)
North Dakota (9)
Northern California (3635)
Ohio (210)
Oklahoma (9)
Oregon (19)
Pennsylvania (1479)
Puerto Rico (4)
Rhode Island (18)
South America (221)
South Carolina (18)
Southern California (2654)
Tennessee (55)
Texas (1041)
United States (25203)
Utah (126)
Virginia (151)
Washington D.C. (38)
Washington State (662)
West Virginia (1)
Wisconsin (69)
288,258 Results for "facio therapies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
pipeline
Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
February 5, 2026
·
2 min read
·
Tristan Manalac
Cell therapy
After Cell Therapy Retreat, Novo Offloads Technologies in Deepened Aspect Pact
Novo Nordisk pulled back from cell therapies last October, scrapping development of a type 1 diabetes therapy and laying off most employees working on this modality.
January 21, 2026
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
January 26, 2026
·
2 min read
·
Dan Samorodnitsky
Cell Therapy
6 Companies Hanging On in Cell Therapy
As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go.
December 1, 2025
·
9 min read
·
Tristan Manalac
gene therapy
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just as regulatory and government policies spark momentum and frustration.
January 28, 2026
·
4 min read
·
Heather McKenzie
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full rights to AbelZeta’s cell therapy for cancer.
January 29, 2026
·
1 min read
·
Tristan Manalac
Opinion
How the FDA Is Accelerating Cell and Gene Therapy’s Next Chapter
Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
November 14, 2025
·
6 min read
·
Anshul Mangal
Opinion
Cell and Gene Therapy Will Transform Lives—If We Let It
Mixed headlines have plagued the cell and gene therapy space of late. We believe that a renewed case of optimism is not only warranted but essential if these therapies are to reach their full potential.
November 24, 2025
·
8 min read
·
Tim Hunt
Rare diseases
FDA Greenlights First Gene Therapy for Rare Pediatric Disease
Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a non-profit sponsor to win FDA approval.
December 10, 2025
·
1 min read
·
Tristan Manalac
Rare diseases
FDA Unwraps ‘Plausible Mechanism Pathway’ for Personalized Therapies
The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed.
November 13, 2025
·
3 min read
·
Tristan Manalac
1 of 28,826
Next
